APP and Alzheimer disease: In one instance, JTR-009, a benzimidazole, was found to limit amyloid burden in mouse models of AD by reducing the production of toxic Aβ in SH-SY5Y neuronal cells more than other well-tolerated APP 5′-UTR directed translation blockers, such as posiphen and phenserine [115].